JP2019520058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520058A5 JP2019520058A5 JP2018561062A JP2018561062A JP2019520058A5 JP 2019520058 A5 JP2019520058 A5 JP 2019520058A5 JP 2018561062 A JP2018561062 A JP 2018561062A JP 2018561062 A JP2018561062 A JP 2018561062A JP 2019520058 A5 JP2019520058 A5 JP 2019520058A5
- Authority
- JP
- Japan
- Prior art keywords
- flavivirus
- analog
- protein
- analogue
- den
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710831 Flavivirus Species 0.000 claims 22
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 20
- 101710145006 Lysis protein Proteins 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 10
- 230000012743 protein tagging Effects 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 108020004511 Recombinant DNA Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000001490 Dengue Diseases 0.000 claims 3
- 206010012310 Dengue fever Diseases 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 3
- 241000907316 Zika virus Species 0.000 claims 3
- 208000025729 dengue disease Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 206010054261 Flavivirus infection Diseases 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608896.5A GB2550418A (en) | 2016-05-20 | 2016-05-20 | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| GB1608896.5 | 2016-05-20 | ||
| PCT/US2017/033882 WO2017201543A1 (en) | 2016-05-20 | 2017-05-22 | Variant flavivirus envelope sequences and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520058A JP2019520058A (ja) | 2019-07-18 |
| JP2019520058A5 true JP2019520058A5 (enExample) | 2020-07-02 |
| JP7121396B2 JP7121396B2 (ja) | 2022-08-18 |
Family
ID=56369688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561062A Active JP7121396B2 (ja) | 2016-05-20 | 2017-05-22 | バリアントフラビウイルスエンベロープ配列およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11028133B2 (enExample) |
| EP (2) | EP3458471B1 (enExample) |
| JP (1) | JP7121396B2 (enExample) |
| KR (1) | KR20190008896A (enExample) |
| CN (1) | CN109415414A (enExample) |
| AU (1) | AU2017268479B2 (enExample) |
| BR (1) | BR112018073681A2 (enExample) |
| CA (1) | CA3025076A1 (enExample) |
| DK (1) | DK3458471T3 (enExample) |
| GB (2) | GB2550418A (enExample) |
| HU (1) | HUE049543T2 (enExample) |
| IL (1) | IL263054A (enExample) |
| MX (1) | MX2018014198A (enExample) |
| PE (1) | PE20190130A1 (enExample) |
| PH (1) | PH12018502441A1 (enExample) |
| RU (1) | RU2018142835A (enExample) |
| SG (1) | SG11201810157QA (enExample) |
| WO (2) | WO2017201543A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| EP3838290A1 (en) * | 2016-06-23 | 2021-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine compositions comprising an attenuated mutant zika virus |
| US11793873B2 (en) * | 2017-05-10 | 2023-10-24 | University Of Massachusetts | Bivalent dengue/hepatitis B vaccines |
| TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | 國立清華大學 | 茲卡病毒疫苗組合物及其應用 |
| CN109627294B (zh) * | 2018-12-29 | 2020-10-09 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
| WO2020198865A1 (en) * | 2019-04-03 | 2020-10-08 | The University Of British Columbia | Oligopeptides for quantitative viral proteomic analysis methods and uses |
| MX2022005498A (es) * | 2019-11-07 | 2022-08-11 | Inst Microbiology Cas | Vacuna del zika/dengue y aplicación de la misma. |
| AU2021357746A1 (en) * | 2020-10-07 | 2023-06-15 | Ctk Biotech, Inc. | Improved diagnostic tests |
| GB202019843D0 (en) | 2020-12-16 | 2021-01-27 | Coronex Ltd | Lateral flow tests |
| EP4602057A1 (en) * | 2022-10-11 | 2025-08-20 | University of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| WO2007015783A2 (en) * | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7943148B1 (en) * | 2007-04-04 | 2011-05-17 | The United States Of America As Represented By The Secretary Of The Army | Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines |
| WO2013151764A1 (en) * | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
-
2016
- 2016-05-20 GB GB1608896.5A patent/GB2550418A/en not_active Withdrawn
-
2017
- 2017-05-22 SG SG11201810157QA patent/SG11201810157QA/en unknown
- 2017-05-22 RU RU2018142835A patent/RU2018142835A/ru not_active Application Discontinuation
- 2017-05-22 CN CN201780040802.7A patent/CN109415414A/zh active Pending
- 2017-05-22 BR BR112018073681-3A patent/BR112018073681A2/pt not_active IP Right Cessation
- 2017-05-22 KR KR1020187036317A patent/KR20190008896A/ko not_active Abandoned
- 2017-05-22 US US16/303,588 patent/US11028133B2/en not_active Expired - Fee Related
- 2017-05-22 PE PE2018003079A patent/PE20190130A1/es unknown
- 2017-05-22 EP EP17726515.4A patent/EP3458471B1/en not_active Not-in-force
- 2017-05-22 DK DK17726515.4T patent/DK3458471T3/da active
- 2017-05-22 MX MX2018014198A patent/MX2018014198A/es unknown
- 2017-05-22 HU HUE17726515A patent/HUE049543T2/hu unknown
- 2017-05-22 CA CA3025076A patent/CA3025076A1/en active Pending
- 2017-05-22 AU AU2017268479A patent/AU2017268479B2/en not_active Ceased
- 2017-05-22 JP JP2018561062A patent/JP7121396B2/ja active Active
- 2017-05-22 WO PCT/US2017/033882 patent/WO2017201543A1/en not_active Ceased
- 2017-11-22 GB GBGB1719423.4A patent/GB201719423D0/en not_active Ceased
-
2018
- 2018-05-22 EP EP18725547.6A patent/EP3630796A1/en not_active Withdrawn
- 2018-05-22 US US16/615,788 patent/US11401307B2/en active Active
- 2018-05-22 WO PCT/EP2018/063422 patent/WO2018215495A1/en not_active Ceased
- 2018-11-15 IL IL263054A patent/IL263054A/en unknown
- 2018-11-20 PH PH12018502441A patent/PH12018502441A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520058A5 (enExample) | ||
| RU2018142835A (ru) | Вариантные последовательности оболочки флавивируса и пути их применения | |
| JP6018575B2 (ja) | デングウイルス組換えサブユニットスワクチン | |
| US20250171501A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| KR101500017B1 (ko) | 재조합 ｈｃｖ ｅ2 당단백질 | |
| AU2007246076B2 (en) | Methods for the treatment of flavivirus infection, molecules and uses thereof | |
| US10098943B2 (en) | Flavivirus virus like particle | |
| US20110129498A1 (en) | Vaccine for the prevention and therapy of hcv infections | |
| WO2002086101A2 (en) | Core-glycosylated hcv envelope proteins | |
| AU2002257392A1 (en) | Core-glycosylated hcv envelope proteins | |
| JP2001511459A (ja) | フラビウイルス感染に対抗する組換え二量体エンベロープワクチン | |
| KR20230009445A (ko) | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 | |
| JP2020509770A5 (enExample) | ||
| Ganguly et al. | Enhanced prokaryotic expression of dengue virus envelope protein | |
| KR20140036127A (ko) | 조성물 및 방법 | |
| CN1202201A (zh) | 抗登革热的多价疫苗 | |
| JP4417712B2 (ja) | ウイルスに対する作用を誘導するタンパク質をコードするキメラ鎖 | |
| CN107074968B (zh) | 疫苗 | |
| CN114409742B (zh) | 非洲猪瘟病毒p49蛋白抗原表位及其应用 | |
| US20250002566A1 (en) | Polynucleotide, expression cassette, vector, host cell, polypeptide, pharmaceutical composition, use of a polypeptide, method for producing a polypeptide, and method for preventing or treating infections caused by flaviviruses | |
| Aghasadeghi et al. | Evaluation of a native preparation of HCV core protein (2-122) for potential applications in immunization, diagnosis and mAb production | |
| Choe | Structure-based antiviral drug discovery | |
| WO2025101636A1 (en) | Flavivirus vaccine composition | |
| WO2017031280A1 (en) | Fusion proteins that include dengue antigens and methods of use | |
| JP2004509071A (ja) | 収束コンビナトリーペプチドライブラリおよびｃ型肝炎ウイルスに対してのワクチン化のためのその使用 |